IMVT Strangle Strategy
IMVT (Immunovant, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT (Immunovant, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.95B, a beta of 0.70 versus the broader market, a 52-week range of 13.63-30.16, average daily share volume of 1.4M, a public-listing history dating back to 2019, approximately 362 full-time employees. These structural characteristics shape how IMVT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.70 places IMVT roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on IMVT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current IMVT snapshot
As of May 15, 2026, spot at $27.51, ATM IV 74.90%, IV rank 40.07%, expected move 21.47%. The strangle on IMVT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on IMVT specifically: IMVT IV at 74.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 21.47% (roughly $5.91 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IMVT expiries trade a higher absolute premium for lower per-day decay. Position sizing on IMVT should anchor to the underlying notional of $27.51 per share and to the trader's directional view on IMVT stock.
IMVT strangle setup
The IMVT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IMVT near $27.51, the first option leg uses a $29.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IMVT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IMVT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $29.00 | $2.05 |
| Buy 1 | Put | $26.00 | $1.93 |
IMVT strangle risk and reward
- Net Premium / Debit
- -$397.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$397.50
- Breakeven(s)
- $22.03, $32.98
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IMVT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IMVT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$2,201.50 |
| $6.09 | -77.9% | +$1,593.35 |
| $12.17 | -55.8% | +$985.20 |
| $18.25 | -33.6% | +$377.05 |
| $24.34 | -11.5% | -$231.10 |
| $30.42 | +10.6% | -$255.75 |
| $36.50 | +32.7% | +$352.40 |
| $42.58 | +54.8% | +$960.56 |
| $48.66 | +76.9% | +$1,568.71 |
| $54.74 | +99.0% | +$2,176.86 |
When traders use strangle on IMVT
Strangles on IMVT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMVT chain.
IMVT thesis for this strangle
The market-implied 1-standard-deviation range for IMVT extends from approximately $21.60 on the downside to $33.42 on the upside. A IMVT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IMVT IV rank near 40.07% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on IMVT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, IMVT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IMVT-specific events.
IMVT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IMVT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IMVT alongside the broader basket even when IMVT-specific fundamentals are unchanged. Always rebuild the position from current IMVT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IMVT?
- A strangle on IMVT is the strangle strategy applied to IMVT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IMVT stock trading near $27.51, the strikes shown on this page are snapped to the nearest listed IMVT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IMVT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IMVT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 74.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$397.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IMVT strangle?
- The breakeven for the IMVT strangle priced on this page is roughly $22.03 and $32.98 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IMVT market-implied 1-standard-deviation expected move is approximately 21.47%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IMVT?
- Strangles on IMVT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMVT chain.
- How does current IMVT implied volatility affect this strangle?
- IMVT ATM IV is at 74.90% with IV rank near 40.07%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.